Taken together, these findings suggest that whether congenital, sporadic, or arising in response to therapy, mutations in MMR genes significantly affect the overall TMB in both IDH-mutant astrocytomas and IDH-wild-type glioblastomas but may only influence clinical outcomes in IDH-mutant astrocytomas. This evidence concerns the gene IDH2 and astrocytoma (excluding glioblastoma).